Clinical Trial Update: HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody [EARLY_Phase 1]

View source ↗

Summary

An early-phase trial evaluating HER2 expression detection and radionuclide therapy in breast cancer using a 99mTc/188Re-labeled single-domain antibody has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 99mTc/188Re-labeled single-domain antibody targeting HER2 (HER2-targeted single-domain antibody labeled with technetium-99m and rhenium-188)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Breast Cancer, Radiotoxicity | EARLY_Phase 1 | Status: COMPLETED